By concurrently reducing glutathione (GSH) and increasing reactive oxygen species (ROS), SeSA-DCA can effectively inhibit the activity of HDAC, p-PDH, and CDC25A both in vitro and in vivo, blocking PCa cell lines in the G1 phase, and induce cell apoptosis, thus exhibiting a promising anti-cancer effect both in vitro and in vivo. Here, HDAC9 is linked to cancer.